ClinicalTrials.gg
RecruitingNCT07815665HARMONi-GU1Updated Sep 11, 2026

A Study of Ivonescimab in Combination With Enfortumab Vedotin vs Pembrolizumab in Combination With Enfortumab Vedotin in Metastatic Urothelial Carcinoma

A Phase 2/3 interventional study of Ivonescimab Dose 1 and enfortumab vedotin (EV) in Metastatic Urothelial Carcinoma and Metastatic Urothelial Carcinoma (UC), sponsored by Summit Therapeutics. Recruiting at 7 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-11.

Sponsored by Summit Therapeutics · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
800
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 360 studies in Carcinoma, Transitional Cell with a site in United States — 77 open to participants now, 140 under way, 14 of them phase 3. Carcinoma, Transitional Cell · United States.

Planned enrollment
11th of 333
800 · median 46
Started
2026
with 21 others
Phase 2/3
7 of 360
3 open now
Primary completion
2030-10
later than 130 of 139 live
Registered
357th of 360
by date

Among the 360 studies in Carcinoma, Transitional Cell with a site in United States, this one is the 11th largest by planned enrollment of the 333 interventional ones that give a count, is one of 22 that started in 2026, is one of 7 in phase 2/3, reaches primary completion later than 130 of the 139 other live ones, and was the 357th registered.

Carcinoma, Transitional Cell

632 studies on the registry are indexed under Carcinoma, Transitional Cell; 180 are open to participants now.

Browse Carcinoma, Transitional Cell studies →

Open to participants now

77 of the 360 studies in Carcinoma, Transitional Cell with a site in United States are open now. Recruiting first, the newest first:

71 more — sign in →

All 77 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 147 Carcinoma, Transitional Cell studies recruiting now, 121 (82%) set no upper age limit and 11 (7%) stop at 75 or younger; 4 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 360 studies in Carcinoma, Transitional Cell with a site in United States, or all of them as a file.
02

Study summary

A Randomized, Open-Label, Multicenter, Phase 2/3 Clinical Study of Ivonescimab in Combination with Enfortumab Vedotin vs Pembrolizumab in Combination with Enfortumab Vedotin in Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma (HARMONi-GU1)

Read the detailed description

This Phase 2/3 study will be conducted in 2 parts. The first part is a Phase 2 randomized, open-label, 2 dose levels, parallel-arm study with the primary objective to evaluate safety and identify the recommended Phase 3 dose (RP3D) of ivonescimab in combination with EV. The second part is a randomized, open-label Phase 3 study with the primary objective to evaluate the efficacy and safety of ivonescimab (RP3D) plus EV versus pembrolizumab plus EV in patients with previously untreated LA/mUC.

For Phase 2 portion, patients will be randomized 1:1 to two arms consisting of 2 different dosages of ivonescimab.

  • Arm A: Ivonescimab Dose 1 + EV
  • Arm B: Ivonescimab Dose 2 + EV For Phase 3 portion, patients will be randomized 1:1 to the experimental arm (ivonescimab + EV) and the control arm (pembrolizumab + EV).
  • Arm 1 (experimental): Ivonescimab RP3D + EV
  • Arm 2 (SoC): Pembrolizumab 200 mg + EV
03

Conditions studied

  • Metastatic Urothelial Carcinoma
  • Metastatic Urothelial Carcinoma (UC)

Keywords

  • LA/mUC
  • Ivonescimab
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years and older
  • 0-1
  • ≥ 6 months
  • documented unresectable LA/mUC (transitional cell carcinoma) of the bladder, renal pelvis, ureter, or urethra with ≥50% urothelial carcinoma component
  • No prior systemic therapy for LA/mUC
  • At least one measurable non-cerebral lesion according to v1.1
  • Adequate organ function

Exclusion criteria

Exclusion Criteria:

  • Locally advanced disease that is resectable or suitable for local therapy with curative intent.
  • Tumors containing any small cell or neuroendocrine differentiation
  • Ongoing sensory or motor neuropathy Grade 2 or higher.
  • Radiographic findings consistent with a high risk of bleeding
  • History of perforation of the gastrointestinal tract and/or fistula, history of gastrointestinal obstruction, extensive bowel resection within 6 months prior to first dose.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
800 participants (estimated)

Study arms

  • Experimental
    Phase 2: Arm A

    Ivonescimab Dose 1 + EV

    Drug: Ivonescimab Dose 1 · Drug: enfortumab vedotin (EV)

  • Experimental
    Phase 2: Arm B

    Ivonescimab Dose 2 + EV

    Drug: enfortumab vedotin (EV) · Drug: Ivonescimab Dose 2

  • Experimental
    Phase 3: Arm 1

    Ivonescimab RP3D (recommended Phase 3 dose) + EV

    Drug: enfortumab vedotin (EV) · Drug: Ivonescimab RP3D

  • Active comparator
    Phase 3: Arm 2

    Pembrolizumab 200 mg + EV

    Drug: enfortumab vedotin (EV) · Drug: Pembrolizumab

Interventions

  • DrugIvonescimab Dose 1

    First ivonescimab dose to be tested in Phase 2

  • Standard of care therapy

  • 200 mg

  • DrugIvonescimab Dose 2

    Second Ivonescimab dose to be tested in Phase 2 part of the study

  • DrugIvonescimab RP3D

    Recommended Phase 3 dose of Ivonescimab after Phase 2 data analysis

06

What researchers measure

Primary outcomes

  1. Phase 2 Primary Outcome Measure

    Adverse events (AEs) as characterized by type, incidence, severity, seriousness, and relationship to study treatment

    Time frame: Through 90 days after the last study treatment

  2. Phase 2 Primary Outcome Measure

    Number of participants with clinical laboratory abnormalities

    Time frame: From first dose until approximately 30 days after the last study treatment, assessed up to 3 years

  3. Phase 2 Primary Outcome measure

    Objective response rate (ORR)

    Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 3 years

  4. Phase 2 Primary Outcome Measure

    PK characteristics: ivonescimab serum concentration profiles

    Time frame: From first dose until end of treatment, assessed up to 3 years

  5. Phase 3 Primary Outcome Measure

    PFS per RECIST v1.1 by Independent Radiology Review Committee (IRRC)

    Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 3 years.

  6. Phase 3 Primary Outcome Measure

    Overall Survival (OS)

    Time frame: From date of randomization until the end of study, assessed up to 4 years

Secondary outcomes

  1. Phase 2 Secondary Outcome Measure

    PFS per RECIST v1.1 by investigator

    Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 3 years

  2. Phase 2 Secondary Outcome Measure

    Overall Survival (OS)

    Time frame: From date of randomization until the end of study, assessed up to 4 years

  3. Phase 2 Secondary Outcome Measure

    Duration of Response (DOR)

    Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 3 years

  4. Phase 2 Secondary Outcome Measure

    Incidence of anti-drug antibodies (ADA) against ivonescimab

    Time frame: From time of initiation of first dose to 30 days after end of treatment.

  5. Phase 3 Secondary Outcome Measure

    ORR

    Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 3 years

  6. Phase 3 Secondary Outcome Measure

    DOR

    Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 3 years

  7. Phase 3 Secondary Outcome Measure

    AEs as characterized by type, incidence, severity, seriousness, and relationship to study treatment

    Time frame: Through 90 days after the last study treatment

  8. Phase 3 Secondary Outcome Measure

    Number of participants with clinical laboratory abnormalities

    Time frame: From first dose until approximately 30 days after the last study treatment, assessed up to 3 years

  9. Phase 3 Secondary Outcome Measure

    PK characteristics: ivonescimab serum concentration profiles

    Time frame: From first dose until end of treatment, assessed up to 3 years

  10. Phase 3 Secondary Outcome Measure

    Incidence of ADA against ivonescimab

    Time frame: From time of initiation of first dose to 30 days after end of treatment

07

Study locations

2 of 7 sites recruiting
  • Research Site
    Phoenix, Arizona 85054, United States
    Not yet recruiting
  • Research Site
    Los Angeles, California 90067, United States
    Recruiting
  • Research Site
    Washington D.C., District of Columbia 20010, United States
    Not yet recruiting
  • Research Site
    Jacksonville, Florida 32224, United States
    Not yet recruiting
  • Research Site
    Rochester, Minnesota 55905, United States
    Not yet recruiting
  • Research Site
    Nashville, Tennessee 37203, United States
    Not yet recruiting
  • Research Site
    Spokane, Washington 99208, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — Not provided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2026; primary completion for Oct 2030, 49 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 31, 2026
First posted
Sep 11, 2026
StartEst.
Sep 10, 2026
Primary completionEst.
Oct 31, 2030
CompletionEst.
Dec 31, 2030
Last update
Sep 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07815665
Lead sponsor
Summit Therapeutics
Responsible party
Sponsor
First posted
Sep 11, 2026
Start date
Sep 10, 2026 (estimated)
Primary completion
Oct 31, 2030 (estimated)
Completion
Dec 31, 2030 (estimated)
Last update
Sep 11, 2026

Study contacts

Summit Clinical Trial Information
Contact
medicalinformation@smmttx.com
1-833-256-0522

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion